hyperhidrosis epidemiology forecast
Hyperhidrosis Insights and Trends
- In 2025, the total number of diagnosed prevalent cases of hyperhidrosis in the 7MM was around 14 million. Among the 7MM countries, the Japan accounted for ~5 million cases.
- Female predominance is consistently observed across the 7MM, with females accounting for the majority of hyperhidrosis cases. This disparity is primarily associated with higher healthcare-seeking behavior among women, greater reporting of quality-of-life–impacting symptoms, and an increased likelihood of receiving a clinical diagnosis.
- The true epidemiological burden of hyperhidrosis remains underestimated due to underdiagnosis and delayed diagnosis, driven by limited disease awareness, social stigma, normalization of excessive sweating, and low healthcare-seeking behavior. Many patients experience symptoms for years before seeking medical care, contributing to prolonged disease burden and delayed treatment initiation.
- Younger adults represent the largest diagnosed hyperhidrosis population, with the 18-39 years age group accounting for the largest share across the major markets. This reflects the typical onset of primary hyperhidrosis during childhood or adolescence and the substantial disease burden during socially and economically productive years.
- Primary (idiopathic) hyperhidrosis accounts for more than 90% of cases, with axillary involvement representing the predominant component of the disease burden. In contrast, secondary hyperhidrosis constitutes a relatively small proportion of cases and is primarily associated with underlying medical conditions or medications, requiring identification and management of the contributing cause.
DelveInsight’s “Hyperhidrosis – Epidemiology Forecast – 2036” report delivers an in depth understanding of hyperhidrosis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
- North America: The United States
- Europe: Germany, France, Italy, Spain and the United Kingdom
- Asia-Pacific: Japan
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2025 |
|
Geographies Covered |
|
|
Hyperhidrosis Epidemiology Segmentation Analysis |
Patient Burden Assessment
|
Hyperhidrosis Understanding
Hyperhidrosis Overview and Diagnosis
Hyperhidrosis is characterized by sweating beyond thermoregulatory requirements and is broadly classified as primary, occurring without an identifiable underlying cause, or secondary, resulting from an underlying medical condition or medication. Primary hyperhidrosis typically presents as localized, bilateral sweating, most commonly affecting the axillary, palmar, plantar, or craniofacial regions, with substantial impact on daily functioning and quality of life.
Diagnosis is primarily clinical and requires differentiation of primary from secondary hyperhidrosis. Key features supporting primary hyperhidrosis include early onset, bilateral and symmetrical localized sweating, absence of excessive sweating during sleep, chronicity, recurrent episodes, family history, and interference with daily activities. Assessment may be supplemented by gravimetry, transepidermal water loss (TEWL), and Minor’s starch-iodine test, while Hyperhidrosis Disease Severity Scale (HDSS), Hyperhidrosis Impact Questionnaire (HHIQ), and Dermatology Life Quality Index (DLQI) can be used to assess disease severity and quality-of-life impact.
Further details related to country-based variations are provided in the report…
Hyperhidrosis Epidemiology
Key Findings from Hyperhidrosis Epidemiological Analysis and Forecast
- According to DelveInsight analysis, nearly 40% males and 60% females were affected with hyperhidrosis in the US in 2025, depicting a clear gender disparity due to hormonal factors.
- The 18-39 years age group represented the largest diagnosed prevalent population in EU4 and the UK, with nearly 2 million cases in 2025, followed by the 40-64 years age group, highlighting the substantial burden among the working-age population.
- Axillary hyperhidrosis accounted for the largest site-specific diagnosed prevalent population in Japan in 2025, with more than 3 million cases, followed by craniofacial, palmar, plantar, and other sites.
Industry Experts and Physician Views for Hyperhidrosis
To keep up with hyperhidrosis patient trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on hyperhidrosis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the St John's Institute of Dermatology, St George’s Hospital, Hôpital Saint-Louis, and Aichi Medical University School of Medicine etc. etc. were contacted.
|
Region |
Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) |
|
Japan |
“Japan's hot and humid climate is an important environmental factor that can aggravate the burden of hyperhidrosis. During the extended summer and monsoon seasons, patients often experience worsening symptoms that interfere with daily activities, work productivity, and social interactions. As rising temperatures and humidity continue to increase heat stress, there is likely to be greater recognition of the disease and a growing preference for effective, convenient therapies that provide sustained symptom control while minimizing treatment burden.” |
|
UK |
“Across Europe, hyperhidrosis remains underrecognized, with underdiagnosis and limited epidemiological data constraining accurate disease burden assessment. Germany shows a marked gap between survey-based prevalence and claims-based diagnoses, while the absence of dedicated registries in countries such as Spain limits robust estimates. In the UK, variability in referral pathways and specialist access may further contribute to diagnostic delays.” |
Scope of the Report
- The report covers a segment of an executive summary, a descriptive overview of hyperhidrosis, explaining its causes, signs, symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- Hyperhidrosis Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
FAQs
- What are the disease risks, burdens, and unmet needs of hyperhidrosis?
- What will be the growth opportunities across the 7MM concerning the patient population with hyperhidrosis?
- What is the hyperhidrosis prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What is the historical and forecasted hyperhidrosis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on hyperhidrosis burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
- Clear methodology, validated assumptions, and data-driven rationale to assess the hyperhidrosis epidemiology analysis and patient population trends.
